QPPV and Its Implication for China's Adverse Drug Reaction Monitoring Work

Abstract

Abstract: Objective To provide suggestions for china to setup and improve the Contact Person of ADR through the brief introduction of Qualified Person for Pharmacovigilance (QPPV). Methods Based on literature review, the QPPV of EU and Australia was investigated and analyzed. Results QPPV has been set up in EU and Australia, it can provide valuable practical experience for our country to establish the Contact Person of ADR. Conclusion Combing with the feature of drug safety supervision in our country and using for reference of the international experience, we should establish and complete our country's Contact Person of ADR in order to improve the level of adverse drug reaction monitoring.

Key words: EU, QPPV, the Contact Person of ADR, implication

CLC Number:

PENG Li-li，SHEN Lu，DONG Duo，LIU Wei，ZHANG Hua，GUO Xue，LI Xing-ling，CHENG Gang. QPPV and Its Implication for China's Adverse Drug Reaction Monitoring Work[J]. Chinese Journal of Pharmacovigilance, 2015, 12(2): 89-91.

References

[1] 杨延音,董至,夏永鹏,等.《药品不良反应报告和监测管理办法》下药品生产企业不良反应监测工作模式探讨[J].中国中药杂志,2012,37（21）:3329-3333.
[2] 卫生部.药品不良反应报告和监测管理办法[EB/OL].(2004-03-04)[2007-10-01].http://www.sfda.gov.cn/ws01/cl0053/24477.
[3] European Medicines Agency.Commission Implementing Regulation(EU) No 520/2012[EB/OL]. (2012-06-19)[2014-06-17].http://eurx.europa.eu/lexUriServ/LexUriServ.douri=OJ:L:2012:159:0005:0025:EN:PDF.
[4] European Medicines Agency. 2010 pharmacovigilance legislation[EB/OL]. (2014-04-16)[2014-08-15].http://www.ema.europa.eu/ema/index.jspcurl=pages/regulation/general/general_content_000492.jsp&mid=WC0b01ac058033e8ad.
[5] European Medicines Agency. GVP Module II Pharmacovigilance System Master File[EB/OL].(2012-06-22)[2014-04-17].http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129133.
[6] 董铎,吴桂芝,程刚.欧盟新法规下的药物警戒制度简介[J].中国药物警戒，2012，9（11）:662-664.
[7] Managing Risk between CRO and Sponsor Organisations.The Role of the Contracted Qualified Person for Pharmacovigilance (QPPV)[J].L. Bolitho in Drug Safety，2008，31(10):885-960.
[8] Therapeutic Goods Administration.Australian Guideline for Pharmacovigilance Responsibilities of Sponsors of Registered Medicines Regulated by Drug Safety and Evaluation Branch[EB/OL].(2005-05-01)[2014-10-21].http://agencysearch.australia.gov.au/s/search.html.
[9] Barton L.Cobert. Pharmacovigilance and Drug Safety for the UK and Europe.Manual of Drug Safety and Pharmacovigilance[EB/OL].(2012-06-22)[2014-04-17]. http://www.pharmacovigilance.org.uk/tag/qppv/.
[10] 孙骏，王越，徐厚明.制药企业在药品不良反应监测工作中承担职责的探讨[J].药物警戒,2006,3（1）:15-17.
[11] 谢金洲.制药企业在药品不良反应监测中的地位和作用[J].食品和药品,2005,7（1）:71-73.

[1]	BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140.
[2]	CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin. One case of interstitial pneumonia caused by serplulimab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
[3]	CAO Shan, PANG Bo, XU Yingli, ZHANG Jingsheng, CHEN Mengping, ZHANG Yu, WANG Yaxin, BAO Lei, GENG Zihan, GUO Shanshan, ZHAO Ronghua, CUI Xiaolan. Effects of Shufeng Jiedu capsules prophylactic administration on TLR4-mediated inflammatory injury in lung tissue in a mouse model of inffuenza virus infeciton [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 45-50.
[4]	ZHANG Jingsheng, GAO Shuangrong, PANG Bo, LIU Lina, XU Yingli, CAO Shan, CHEN Mengping, ZHANG Yu, ZHAO Ronghua, CUI Xiaolan. The mechanism of Sanhan Huashi Granules on pneumonia induced by human coronavirus 229E and OC43 in mice [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 51-54.
[5]	WANG Lyuyin, LI Yi, SUN Yue, HU Xinyue, ZHANG Hui, LI Jing, LIANG Chenggang. Determination of sialic acid in recombinant human follicle stimulating hormone by high performance liquid chromatography with DMB derivatization [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 89-93.
[6]	ZHANG Li, WANG Yujia, ZHANG Lingling, CHEN Jiaxin, LIN Minhua, LIN Xiaohui, NIE Xuekun. Surveillance data on adverse reactions associated with real-world immune checkpoint inhibitors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1035-1038.
[7]	ZHANG Yuqi, XU Xinyi, ZHU Lan, ZHU Yan. Comparison standard terminology for pharmaceutical dose forms [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 904-910.
[8]	ZHANG Xialan, YUAN Jing, WU Bin, QIN Yuanyuan. Medications of apatinib mesylate in patients with malignant tumors [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 927-932.
[9]	WANG Ran, LI Yifan, LIU Xiaoyan, FENG Xin. One case of pharmaceutical care of drug exposure during pregnancy [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 933-934.
[10]	WU Lingfang, TIAN Wei, MA Yongben, GAO Le, SUN Zheng, WANG Xinguo, NIU Liying. Determination of seven main components in aqueous extract of Bupleuri Radix-Paeoniae Alba Radix by UPLC-PDA [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 769-774.
[11]	ZHANG Lei, LYU Jian, XIE Yanming. Efficacy and safety of Houpupaiqi Mixture in the treatment of postoperative lieus: a Meta-analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 799-806.
[12]	LIU Jing, XIA Liang, ZHANG Shijie. Pharmaceutical care of a patient with acute pancreatitis complicated with multiple drug allergy undergoing drug stimulation test [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 822-824.
[13]	WANG Ran, FENG Xin, DU Boran. Advances in risk assessment and pharmaceutical care of pregnancy medication exposure during perinatal period [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 836-840.
[14]	LIU Jingjing, DAI Zhong, YANG Jianbo, WANG Ying, XU Beilei, LIU Yue, WANG Qi, MA Shuangcheng. Spectrum-fect relationship of Ginseng Radix et Rhizoma Rubra and Polygonum Multiflorum Radix Preparata medicinal pair in protection of nerve cells [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 623-628.
[15]	LUO Qiong, LI Meng, LI Guangyao, HE Yanchun, ZHOU Zushan, SUN Xin, LIU Chenghai. Chinese medical evidence and characteristics of combined medication in 635 cases of rheumatoid arthritis patients with liver injury caused by the application of Tripterygium wilfordii preparations [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 500-504.